Fiercepharma | June 17, 2020
On the heels of some big fundraising moves and in the hunt for a COVID-19 vaccine, Novavax is adding some Big Pharma experience to its executive team. Joining the company's leadership team as chief medical officer is Filip Dubovsky, an AstraZeneca veteran. Dubovsky joins Novavax directly from the British drugmaker, where he served as head of clinical engagement and policy, plus as chief medical officer for clinical affairs. Before that role, he oversaw a portfolio of more than two dozen malaria vaccines at the PATH Malaria Vaccine Initiative. Dubrovsky will be tasked with overseeing development of the company's COVID-19 candidate. The company in late May kicked off a phase 1/2 study of the prospect, and it's been working through steps to scale up its manufacturing in parallel. Aside from its COVID-19 work, the company is getting ready to submit an FDA application for its flu vaccine, NanoFlu.
AmerisourceBergen | October 22, 2021
Today, AmerisourceBergen concluded its second annual ThinkLive Trade virtual event, a three-day online summit geared toward brand, specialty, generic and consumer-product manufacturers. Over the course of the event, AmerisourceBergen leaders discussed the ever-evolving challenges and considerations that these manufacturers face when bringing products to market, and how AmerisourceBergen works with its partners to drive supply chain sophistication, maximize patient access, and move health forward. AmerisourceBergen also introduced its new President of Manufacturer Services and Commercial Solutions, Willis Chandler, during the conference – a new role for the organization.“The last two years have proven how dynamic, fast-paced and essential the pharmaceutical industry and supply chain are to advancing global health—from launching new therapies, to maintaining consistent access to daily prescriptions, to providing frontline workers with the products and resources they need to stay safe amid a pandemic,” said Willis Chandler, who recently stepped into the new role as President of Manufacturer Services and Commercial Solutions from leading AmerisourceBergen’s health systems and specialty services organization. “ThinkLive Trade is an opportune time for us connect with manufacturers and dig deeper into their needs, challenges and opportunities in the year ahead. I plan to carry our key learnings from the conference forward, and I cannot wait to bring more novel solutions to the market in collaboration with our manufacturer partners.”
This year’s conference programming included remarks from AmerisourceBergen Chairman, President & CEO Steve Collis, dynamic panel discussions, presentations, awards, virtual networking sessions and more. Content and meetings were facilitated through AmerisourceBergen’s online experience platform, AmerisourceBergenLive.
On the first day of the summit, attendees heard directly from AmerisourceBergen executives and customers on the state of the industry, strategies to improve global health equity, and sustainable and responsible approaches to healthcare advancement. Day two of ThinkLive Trade featured discussions on technology and infrastructure enhancements to drive innovation, supply chain continuity, and AmerisourceBergen’s strategy and focus for the year ahead. The final day of the summit focused on the intersection of healthcare and politics, featuring a fireside chat with, Mark McClellan, MD, PhD, founding Director of the Duke-Margolis Center for Health Policy at Duke University, as well as timely discussions on global generics, specialty pharmaceutical products, biosimilars, and more.
“The resilience of the pharmaceutical supply chain in the face of a global pandemic and evolving market dynamics continues to reinforce the value of strategic relationships, Our partners are developing novel therapeutics, creating pharmaceuticals to manage chronic conditions in patients worldwide, producing essential generics to ensure cost-effective medicines are available in today’s marketing, developing consumer products that are essential to fighting this pandemic and beyond, and so much more. We are thankful for their partnership and to all who attended ThinkLive Trade. This week’s conference encouraged meaningful dialogue that will help us advance healthcare efficiency and supply chain reliability in the year ahead.”
Janine Burkett, SVP & President, Strategic Global Sourcing at AmerisourceBergen.
AmerisourceBergen will also host ThinkLive Commercialization early next year. The event will bring together emerging biotech and biopharma leaders to discuss the latest in launch strategies across different therapeutic categories.
AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies, and providers, we create unparalleled access, efficiency, and reliability for human and animal health. Our 41,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual revenue
STALLERGENES GREER LTD | October 27, 2021
Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced that the company has entered into an exclusive partnership with Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, for the development of the first of its kind connected device and companion mobile app for patients undergoing Stallergenes Greer’s AIT treatments with sublingual solutions.
“This exclusive partnership with Aptar Pharma demonstrates the intensification of Stallergenes Greer’s investments in innovation to provide a large range of precise personalised allergen immunotherapy options adapted to the individual needs and lifestyle of patients. Stallergenes Greer is well advanced on its digital transformation journey and will continue to develop its e-health offering for the benefit of all stakeholders,” stated Dominique Pezziardi, General manager France, Belgium and Luxembourg, Global Head of Pricing and Market Access.
Non-adherence to an AIT schedule and premature discontinuation of treatment remain a challenge in AIT management. This innovative, easy-to-use connected device will contribute to improving dose compliance and adherence, thus optimising treatment outcomes.
The development work is being undertaken by Aptar Pharma’s Digital Health group, which has capabilities and expertise in device and software development. The product will leverage Aptar Pharma’s Cohero platform, which will be tailored specifically for this use.
“We are pleased to combine Aptar Pharma’s Digital Health ecosystem with Stallergenes Greer’s knowledge and leading position in AIT to further improve the treatment journey of patients who suffer from allergiesThe newly developed connected device should be available in France in 2022 and will be progressively rolled-out in Stallergenes Greer’s markets.
Sai Shankar, Vice President, Global Digital Healthcare Systems, Aptar Pharma
This innovation further illustrates Stallergenes Greer’s commitment to build on precision medicine and personalised healthcare which cater to the needs of both patients and the medical community.
ABOUT STALLERGENES GREER LTD
Headquartered in London (UK), Stallergenes Greer Ltd is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergy immunotherapy products and services. Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France).
ABOUT APTAR PHARMA
Aptar Pharma is part of Aptar Group Inc., a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions. Aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has 13,000 dedicated employees in 20 countries.